|
nasdaq:omer
|
64661
|
May 5th, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
234.00
|
Open
|
|
May 4th, 2024 11:56PM
|
May 4th, 2024 11:56PM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:omer
|
64661
|
May 4th, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
234.00
|
Open
|
|
May 3rd, 2024 11:30PM
|
May 4th, 2024 07:10PM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:omer
|
64661
|
May 3rd, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
234.00
|
Open
|
|
May 2nd, 2024 11:26PM
|
May 3rd, 2024 02:56PM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:omer
|
64661
|
May 2nd, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
234.00
|
Open
|
|
May 1st, 2024 11:35PM
|
May 2nd, 2024 10:34AM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:omer
|
64661
|
May 1st, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
234.00
|
Open
|
|
May 1st, 2024 01:24AM
|
May 1st, 2024 09:58AM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:omer
|
64661
|
Apr 30th, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
233.00
|
Open
|
|
Apr 29th, 2024 11:54PM
|
Apr 30th, 2024 08:51AM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:omer
|
64661
|
Apr 29th, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
233.00
|
Open
|
|
Apr 29th, 2024 02:16AM
|
Apr 29th, 2024 09:59AM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:omer
|
64661
|
Apr 28th, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
233.00
|
Open
|
|
Apr 27th, 2024 11:48PM
|
Apr 27th, 2024 11:48PM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:omer
|
64661
|
Apr 27th, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
234.00
|
Open
|
|
Apr 26th, 2024 11:27PM
|
Apr 26th, 2024 11:27PM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:omer
|
64661
|
Apr 26th, 2024 12:00AM
|
Omeros Corporation
|
9.3K
|
234.00
|
Open
|
|
Apr 25th, 2024 11:34PM
|
Apr 26th, 2024 08:55AM
|
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
|
Open
|
|
Open
|
201 Elliott Ave W
|
Seattle
|
WA
|
US
|
98119
|
|
Omeros
|
Health Care
|
Pharmaceuticals & Biotechnology
|